Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the first findings from the CONNECT clinical program on ProAir® Digihaler® (albuterol sulfate) inhalation powder with an integrated electronic module (eModule) will be presented at the European Respiratory Society (ERS) International Congress 2022, held September 4-6 in Barcelona, Spain. The CONNECT1 trial was c

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022

Chipotle

Pinterest

There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let's tune into a few examples.

Volume Surges Spark Turnarounds for These 3 Stocks

Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022.

Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies

Bank of America finds its inner bull with the generics producer.

Why Teva Stock Trounced the Market on Friday

Berkshire Hathaway cut bait with the struggling drugmaker Teva Pharmaceutical Industries in late 2021.

Is This Rare Berkshire Hathaway Miscue Finally a Buy?

Teva posted second-quarter results that exceeded market expectations. Teva's outlook looks bright.

Teva Q2 Earnings: 5 Reasons Why Shares Rose By 30%

One of the world's largest generic drugmakers tries to get past a lengthy legal battle, but it is still struggling to find growth.

Teva Tries to Put an End to the Opioid Wars

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Ran Meir – Senior Vice President, Head of Investor Relations Kare Schultz – Chief Executive Officer Eli Kalif – Chief Financial Officer Sven Dethlefs – Executive Vice President, North America Commercial Conference Call Participants Balaji Prasad – Barclays Nathan Rich – Goldman Sachs Umer Raffat – Evercore Jason Gerberry – Bank of America Ashwani Verma – UBS Elliot Wilbur – Raymond James Gary Nachman – BMO Capital Markets David Amsellem – Piper Sandler Operator Welcome to the Teva's Second Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode.

Teva Pharmaceutical Industries Limited's (TEVA) CEO Kare Schultz on Q2 2022 Results - Earnings Call Transcript

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

Teva Pharma inked settlement deals worth upward of $4 billion for its role in the opioid crisis, and Teva stock skyrocketed on Wednesday. The post Teva Pharmaceutical Soars After Inking More Than $4 Billion In Opioid Deals appeared first on Investor's Business Daily.

Teva Pharmaceutical Soars After Inking More Than $4 Billion In Opioid Deals

Source: JHVEPhoto / Shutterstock.com Teva Pharmaceuticals (NYSE: TEVA ) stock is soaring higher on Wednesday after the pharmaceutical company reached a settlement in recent lawsuits. According to recent reports, Teva Pharmaceuticals is prepared to pay a proposed $4.35 billion to settle lawsuits connected to the opioid crisis in the U.S. That covers $3.7 billion in cash to local governments, $1.2 billion worth of opioid overdose treatment naloxone, as well as other payments.

TEVA Stock Surges 24% as Teva Pharmaceuticals Settles Lawsuits

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are exploding today, after the drugmaker agreed to pay up to $4.25 billion for its alleged role in the U.S. opioid crisis.

Pharma Stock Explodes After Massive Settlement, Earnings

JERUSALEM (Reuters) -Teva Pharmaceutical Industries projected on Wednesday mid-single digit revenue growth over the next five years as it tries to move on from its high debt and an overhang from thousands of lawsuits over its alleged role in the U.S. opioid epidemic.

Teva Pharm sees return to growth post-opioid settlement

Teva Pharmaceutical will pay $75 million over 15 years and provide free opioid overdose treatment for 10 years. Teva stock rocketed.

Teva Pharmaceutical Soars On $75 Million Opioid Deal In West Virginia

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -0.97% soared 25.7% in premarket trading on Wednesday, the day after the company said it will pay $4.25 billion to states, plus an additional $100 million to Native American tribes, over 13 years to resolve most opioid lawsuits it's facing.

Teva's stock jumps 25% after announcing $4.2 billion deal to resolve opioid lawsuits

The drugmaker's opioid litigation may soon be resolved.

Why Teva Pharmaceutical Industries Stock Is On Fire Today

The company will pay up to $4.25 billion spread over 13 years to settle opioid lawsuits.

Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement

Teva Pharmaceutical Industries on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker's alleged role in the US opioid epidemic.

Teva reaches proposed $4.35 billion settlement of US opioid lawsuits

Teva Pharmaceutical Industries announced a $4.25 billion proposed nationwide settlement on Tuesday that could resolve thousands of lawsuits over the drugmaker's alleged role in the U.S. opioid epidemic.

Teva reaches proposed $4.25 billion settlement of U.S. opioid lawsuits

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2022. Mr. Kåre Schultz, Teva's President and CEO: "In the second quarter Teva has delivered a solid performance, despite global macroeconomic headwinds. Our generic and OTC business benefitted from the gradual easing of COVID-19 restrictions in Europe and successful generic launches in the U.S. We also executed well on our key specialty brands, AUSTE

Teva Reports Second Quarter 2022 Financial Results

Alkermes

Biogen

Bristol-Myers

GlaxoSmithKline

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

First Majestic Silver

Bank of America

Lovesac Company

SSR Mining

Despite owning 44 stocks, I have 62.5% of my invested assets in just five companies.

5 Stocks I'm Betting the Farm On

Of the top 10 generic drugmakers in 2021, only one scored an increase in share price during the past year. It was Sun Pharmaceutical Industries Ltd.

With Brighter Outlook, Generics Could Be Ripe for Investment

TEVA stock, already trading far below its prior peak, may come under pressure in the near future due to the threat of ongoing litigation. The post What Is Going on With Teva Pharmaceuticals (TEVA) Stock Today?

What Is Going on With Teva Pharmaceuticals (TEVA) Stock Today?

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the City and County of San Francisco and the People of the State of California that settles opioid-related claims asserted on behalf of the County and City of San Francisco. The settlement will provide San Francisco $24.8 million over 13 years, as well as life-saving medicine generic Narcan® (n

News for Teva Pharmaceutical Stock (TEVA)